Chennai: Pharma Major, Caplin Point Laboratories said that its wholly owned subsidiary Caplin Steriles Limited has entered into a license and supply agreement with Baxter Healthcare Corporation for five generic injectable ANDAs.
Commenting on the transaction, Mr C.C.Paarthipan, Chairman, Caplin Point Laboratories Limited, said ”We are glad to enhance our partnership with Baxter with this agreement. All these ANDAs have been developed in-house, and we’re keen to license them to Baxter, who have an excellent sales and marketing infrastructure in the US for commercialization of these products.”
Specific terms of the agreement were not disclosed.
Latest posts by Garima (see all)
- Ministry of AYUSH invites initial bids for strategic sale of IMPCL - April 18, 2019
- Cipla acquires 30 percent stake in Brandmed for Rs 32 crore - April 18, 2019
- Cancer drugs Darzalex, Imbruvica drive JnJ to better than expected quarterly profit - April 17, 2019